151 related articles for article (PubMed ID: 34647536)
1. [Medicines use in Italy. 2020 OsMed National Report.].
Zito S; Fortinguerra F; Pierantozzi A; Ambrosino F; Traversa G; Trotta F; Da Cas R; Cangini A
Recenti Prog Med; 2021 Oct; 112(10):659-667. PubMed ID: 34647536
[TBL] [Abstract][Full Text] [Related]
2. [About direct and on behalf delivery of drugs.].
De Rosa MM
Recenti Prog Med; 2022 Dec; 113(12):705-714. PubMed ID: 36420846
[TBL] [Abstract][Full Text] [Related]
3. [Biosimilar medicines: OsMed reports on monitoring consumption and spending in Italy.].
Zito S; De Fiore R; Marini R; Cangini A; Perna S; Settesoldi D
Recenti Prog Med; 2021; 112(7):504-509. PubMed ID: 34263877
[TBL] [Abstract][Full Text] [Related]
4. [Medicines use in older adults in Italy. The OsMed National Report 2019.].
Zito S; Pierantozzi A; Marinelli M; Ambrosino F; Trotta F; Cangini A
Recenti Prog Med; 2022 Feb; 113(2):76-83. PubMed ID: 35156949
[TBL] [Abstract][Full Text] [Related]
5. Financial Outcomes of Managed Entry Agreements for Pharmaceuticals in Italy.
Trotta F; Guerrizio MA; Di Filippo A; Cangini A
JAMA Health Forum; 2023 Dec; 4(12):e234611. PubMed ID: 38153808
[TBL] [Abstract][Full Text] [Related]
6. MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY.
Montilla S; Xoxi E; Russo P; Cicchetti A; Pani L
Int J Technol Assess Health Care; 2015 Jan; 31(4):210-3. PubMed ID: 26646859
[TBL] [Abstract][Full Text] [Related]
7. Access and use of WHO essential medicines in Italy.
Petrella A; Fortinguerra F; Cangini A; Pierantozzi A; Trotta F
Front Public Health; 2023; 11():1211208. PubMed ID: 37881343
[TBL] [Abstract][Full Text] [Related]
8. Recovery of suspended reimbursements of high-cost drugs subjected to monitoring registries and negotiated agreements (MEAs): a tool for governance and clinical appropriateness in the Italian reality.
Capuozzo M; Celotto V; Zovi A; Langella R; Ferrara F
Eur J Health Econ; 2024 Feb; 25(1):1-5. PubMed ID: 37878195
[TBL] [Abstract][Full Text] [Related]
9. Economic Impact of Schizophrenia from a Hospital and Social Security System Perspective in Italy.
Mennini FS; Marcellusi A; Gazzillo S; Nardone C; Sciattella P; Migliorini R; Trabucco Aurilio M; Amore M; Brugnoli R
Clin Drug Investig; 2021 Feb; 41(2):183-191. PubMed ID: 33559103
[TBL] [Abstract][Full Text] [Related]
10. The last decade of Italian pharmaceutical policy: instability or consolidation?
Fattore G; Jommi C
Pharmacoeconomics; 2008; 26(1):5-15. PubMed ID: 18088155
[TBL] [Abstract][Full Text] [Related]
11. Current national initiatives about drug policies and cost control in Europe: the Italy example.
Rocchi F; Addis A; Martini N;
J Ambul Care Manage; 2004; 27(2):127-31. PubMed ID: 15069990
[TBL] [Abstract][Full Text] [Related]
12. [Establishing the value of new drugs in Italy.].
Villa F; Jommi C; Altamura G; Antignani S; Cangini A; Fortino I; Melazzini M; Trotta F; Tafuri G
Recenti Prog Med; 2020 Feb; 111(2):65-69. PubMed ID: 32089554
[TBL] [Abstract][Full Text] [Related]
13. Italian Public Health Expenditure for Vitamin D is still high: New Outlook to Saving From a Consumption Analysis in the Liguria Region.
Moretti M; Paleari L; Figallo F; Garbarini C; Ponti E; Schena F; Marinelli L
Clin Ther; 2021 Nov; 43(11):1969-1982. PubMed ID: 34756467
[TBL] [Abstract][Full Text] [Related]
14. Value assessment of medicinal products by the Italian Medicines Agency (AIFA) and French National Authority for Health (HAS): Similarities and discrepancies.
Xoxi E; Di Bidino R; Leone S; Aiello A; Prada M
Front Med Technol; 2022; 4():917151. PubMed ID: 36134249
[TBL] [Abstract][Full Text] [Related]
15. Citizens' views on prices of medicines reimbursed by the National Health Service: Findings from Italian online focus groups.
Colombo C; Caldara D; Banzi R
Health Expect; 2024 Apr; 27(2):e14005. PubMed ID: 38432872
[TBL] [Abstract][Full Text] [Related]
16. Switch from public to private retail pharmaceutical expenditures: evidence from a time series analysis in Italy.
Lenzi J; Gianino MM
BMJ Open; 2022 Mar; 12(3):e055421. PubMed ID: 35260457
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability.
Dylst P; Vulto A; Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):33-42. PubMed ID: 25138241
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of poor quality drug prescribing in older individuals: a nationwide report from the Italian Medicines Agency (AIFA).
Onder G; Bonassi S; Abbatecola AM; Folino-Gallo P; Lapi F; Marchionni N; Pani L; Pecorelli S; Sancarlo D; Scuteri A; Trifirò G; Vitale C; Zuccaro SM; Bernabei R; Fini M;
J Gerontol A Biol Sci Med Sci; 2014 Apr; 69(4):430-7. PubMed ID: 23913935
[TBL] [Abstract][Full Text] [Related]
19. [Direct and on behalf delivery of drugs for human use: opportunities and problems.].
Di Filippo A; Cangini A; Trotta F
Recenti Prog Med; 2022 Sep; 113(9):475-483. PubMed ID: 35939843
[TBL] [Abstract][Full Text] [Related]
20. [The use of antibiotics in Italy. The national OsMed report 2019.].
Fortinguerra F; Ambrosino F; Pierantozzi A; Da Cas R; Trotta F; Cangini A
Recenti Prog Med; 2021 Mar; 112(3):186-190. PubMed ID: 33687356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
